Eaton Vance Worldwide Health Sciences Fund Buys Merck Inc, GlaxoSmithKline PLC, Novartis AG, Sells AbbVie Inc, Bristol-Myers Squibb Company, Biogen Inc

• New Purchases: GSK, NVS, LONN, MDT, MASI, BLUE, ATRA,
• Added Positions: MRK, ABT, BAX, COLO B, NBIX, A, ALXN, INCY,
• Reduced Positions: ABBV, BMY, BIIB, GILD, ROG, UNH, SHP, HUM, REGN, LLY,
• Sold Out: PCRX, AVXS,

For the details of Eaton Vance Worldwide Health Sciences Fund's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Eaton+Vance+Worldwide+Health+Sciences+Fund

1. Johnson & Johnson (JNJ) - 496,664 shares, 6.02% of the total portfolio.
2. UnitedHealth Group Inc (UNH) - 239,444 shares, 5.86% of the total portfolio. Shares reduced by 14.83%
3. Pfizer Inc (PFE) - 1,135,385 shares, 4.14% of the total portfolio.
4. Merck & Co Inc (MRK) - 658,673 shares, 3.98% of the total portfolio. Shares added by 241.28%
5. Bayer AG (BAYN) - 253,183 shares, 3.06% of the total portfolio. Shares reduced by 16.06%

Eaton Vance Worldwide Health Sciences Fund initiated holding in GlaxoSmithKline PLC. The purchase prices were between $12.74 and $15.25, with an estimated average price of $14.14. The stock is now traded at around $15.82. The impact to a portfolio due to this purchase was 2.68%. The holding were 1,306,141 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund initiated holding in Novartis AG. The purchase prices were between $74.96 and $84.29, with an estimated average price of $79.19. The stock is now traded at around $83.69. The impact to a portfolio due to this purchase was 2.22%. The holding were 295,000 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund initiated holding in Lonza Group Ltd. The purchase prices were between $219.8 and $271.6, with an estimated average price of $244.03. The stock is now traded at around $305.30. The impact to a portfolio due to this purchase was 1.51%. The holding were 55,571 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund initiated holding in Medtronic PLC. The purchase prices were between $76.55 and $86.99, with an estimated average price of $81.47. The stock is now traded at around $90.24. The impact to a portfolio due to this purchase was 1.03%. The holding were 117,565 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund initiated holding in Masimo Corp. The purchase prices were between $83.58 and $100.22, with an estimated average price of $90.61. The stock is now traded at around $100.06. The impact to a portfolio due to this purchase was 0.59%. The holding were 58,354 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund initiated holding in bluebird bio Inc. The purchase prices were between $160.45 and $233.05, with an estimated average price of $183.75. The stock is now traded at around $155.50. The impact to a portfolio due to this purchase was 0.26%. The holding were 14,429 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund added to a holding in Merck & Co Inc by 241.28%. The purchase prices were between $53.27 and $60.25, with an estimated average price of $56.93. The stock is now traded at around $65.49. The impact to a portfolio due to this purchase was 2.81%. The holding were 658,673 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund added to a holding in Abbott Laboratories by 37.48%. The purchase prices were between $57.57 and $63.62, with an estimated average price of $60.36. The stock is now traded at around $64.78. The impact to a portfolio due to this purchase was 0.47%. The holding were 276,884 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund added to a holding in Coloplast A/S by 33.59%. The purchase prices were between $496.4 and $617.2, with an estimated average price of $539.65. The stock is now traded at around $707.80. The impact to a portfolio due to this purchase was 0.25%. The holding were 104,124 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund added to a holding in Neurocrine Biosciences Inc by 72.52%. The purchase prices were between $75.3 and $95.64, with an estimated average price of $85.02. The stock is now traded at around $113.55. The impact to a portfolio due to this purchase was 0.24%. The holding were 59,473 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund sold out a holding in Pacira Pharmaceuticals Inc. The sale prices were between $27.5 and $36.7, with an estimated average price of $33.21.

Eaton Vance Worldwide Health Sciences Fund sold out a holding in AveXis Inc. The sale prices were between $115.91 and $217.83, with an estimated average price of $172.63.

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in AbbVie Inc by 59.34%. The sale prices were between $89.78 and $119.75, with an estimated average price of $101.49. The stock is now traded at around $93.91. The impact to a portfolio due to this sale was -2.57%. Eaton Vance Worldwide Health Sciences Fund still held 156,151 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Bristol-Myers Squibb Company by 68.88%. The sale prices were between $50.53 and $67.92, with an estimated average price of $57.67. The stock is now traded at around $59.62. The impact to a portfolio due to this sale was -2.51%. Eaton Vance Worldwide Health Sciences Fund still held 176,060 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Biogen Inc by 41.54%. The sale prices were between $257.52 and $294.4, with an estimated average price of $274.38. The stock is now traded at around $344.06. The impact to a portfolio due to this sale was -1.28%. Eaton Vance Worldwide Health Sciences Fund still held 63,797 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Gilead Sciences Inc by 25.24%. The sale prices were between $64.88 and $81.72, with an estimated average price of $72.89. The stock is now traded at around $77.90. The impact to a portfolio due to this sale was -0.98%. Eaton Vance Worldwide Health Sciences Fund still held 378,226 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Roche Holding AG by 42.99%. The sale prices were between $211.05 and $229.8, with an estimated average price of $220.64. The stock is now traded at around $243.05. The impact to a portfolio due to this sale was -0.96%. Eaton Vance Worldwide Health Sciences Fund still held 56,527 shares as of 2018-05-31.

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Shire PLC by 43.99%. The sale prices were between $29.54 and $42.19, with an estimated average price of $36.76. The stock is now traded at around $43.51. The impact to a portfolio due to this sale was -0.79%. Eaton Vance Worldwide Health Sciences Fund still held 240,939 shares as of 2018-05-31.